Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.

Research scientists working in laboratory

Bisphosphonates, a drug class used to prevent the loss of bone density, are the first-line treatment for preventing fracture in osteoporosis patients. Osteoporosis is often associated with patients with chronic kidney disease (CKD), who can suffer from low bone density and increased fracture risk, but there was little information available on the safety of bisphosphonates in patients with CKD.

Moderate to severe (stages 3-5) chronic kidney disease (CKD) affects up to 2.8 million people in the UK and 2.7 million people in Spain.

The Prieto-Alhambra Group for Pharmaco- and Device Epidemiology at Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMS), in collaboration with SIDIAP, set out to understand the safety profile of bisphosphonates in patients with moderate to severe CKD. Using primary-care electronic records from two patient cohorts in the UK and Catalonia, Spain, they analysed the data from 4,000 bisphosphonate users and more than 15,000 non-users.

Read the full story on the NDORMS website

Similar stories

Professor Dame Sarah Gilbert delivers 44th Dimbleby Lecture

Professor Dame Sarah Gilbert, Saïd Professorship of Vaccinology, Jenner Institute & Nuffield Department of Clinical Medicine, delivered the 44th Richard Dimbleby Lecture, named after the late broadcaster, Richard Dimbleby.

Com-COV2 study supports flexible second dose options following Pfizer or Oxford/AstraZeneca jabs

Following up first doses of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines with second doses of the Moderna or Novavax jabs will generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.

Meta must do better - data from social media giant essential to mental health research

People are rightly sceptical about scientific discoveries made in secret or without scrutiny. And anyone claiming to have found a new planet with a toy telescope, would not be taken seriously. Recent leaks of internal Facebook research on the mental health of children and young people have caused a great stir on both sides of the Atlantic.

New Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease

GlaxoSmithKline plc and the University of Oxford today announced a major five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine.

Oxford researchers honoured by British Society for Immunology

Four researchers from the University of Oxford have been recognised for their outstanding contributions to immunology with Honorary Lifetime Membership of the British Society for Immunology, with the awards being announced at the recent British Society for Immunology Congress held in Edinburgh.

Medical Sciences researchers scoop 2021 Times Higher Education Awards

Coronavirus researchers from across Medical Sciences have been honoured at the 2021 Times Higher Education (THE) Awards.